NCT05954416招募中不适用
National Cohort for Evaluation of the Burden of Rare Skin Diseases
Institut National de la Santé Et de la Recherche Médicale, France14 个研究点 分布在 1 个国家目标入组 900 人开始时间: 2018年3月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 900
- 试验地点
- 14
- 主要终点
- Individual burden score for each selected rare disease
研究概览
简要总结
The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical) for patients and/or families.
Two types of indicators will be used to reach this objective :
- an individual burden score calculated based on a burden questionnaire created specifically, approved and designed to understand the tendency to changes in care and lifestyles. The burden questionnaire should be used by patients and/or their family themselves in self-assessment.
- a descriptive analysis of all resources (medical and non-medical) used by the family unit to manage the disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults or children with a confirmed diagnosis of one of the 9 following rare skin disease: Inherited epidermolysis bullosa, Ichthyosis, Ectodermal dysplasia, Incontinetia Pigmenti, Neurofibromatosis type 1, Albinism, Pemphigus, Mucous membrane pemphigoid or Palmoplantar keratoderma.
- •prevalent or incident and followed in one the reference/competence centers of the FIMARAD healthcare network,
- •able to understand a survey (for child, survey should be understood by parents),
- •having given their signed consent to participate to the cohort RaDiCo-FARD (parents' consent for child).
- •Non-inclusion criteria :
- •Patients, for whom regular care follow-up is not feasible with the FIMARAD healthcare network sites,
- •Unconfirmed diagnosis (according to criteria for each disease),
- •Patients (and/or parents) not able to understand a survey
- •Patients (and/or parents) not having given their signed consent to participate to the study
排除标准
- 未提供
结局指标
主要结局
Individual burden score for each selected rare disease
时间窗: Through study completion, an average of 5 years
Before 16 years old, we will focus on the burden of families. After 16 years old, the patient's parent will continue to answer to the family Burden questionnaire and the patient will start to answer to the adult's Burden questionnaire.
次要结局
- Description of calculated scores based on widely used survey completed by parents(Through study completion, an average of 5 years)
- Descriptive analysis of the socio-economic Burden.(Through study completion, an average of 5 years)
- Description of variations of quality-of-life scores.(Through study completion, an average of 5 years)
- Validation of the clinical severity score for disease which have none at the beginning of the study and description of clinical severity score.(Through study completion, an average of 5 years)
- Descriptive analysis of the Individual Health Care Cost.(Through study completion, an average of 5 years)
- Search for association between individual burden score and clinical severity of the disease.(Through study completion, an average of 5 years)
- Description of calculated scores based on widely used survey completed by patients(Through study completion, an average of 5 years)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
不适用
The National Registry Study For the Real-world Patients With Parkinsonian Disorders in ChinaParkinsonian DisordersNCT03649503Huashan Hospital100,000
已完成
不适用
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune DisordersAuto-immune Thrombocytopenic PurpuraHemolytic Auto-immune AnaemiaCold Agglutinin DiseasePemphigusCryoglobulinemiaNCT00960713University Hospital, Toulouse35
已完成
不适用
Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in ItalyHerpes Zoster VaccineHerpes ZosterNCT01772160GlaxoSmithKline395
已完成
不适用
Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in SpainHerpes ZosterNCT01521286GlaxoSmithKline552
已完成
不适用
Observational Prospective Study OPTIMA II - Follow-upMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)NCT02099565AstraZeneca572